Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults [ID1297]Product type:GuidanceProgramme:Technology appraisal guidanceExpected publication date: 28 July 2021
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1137)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2026
Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal) (TA1135)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 February 2026
Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal) (TA1132)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 February 2026
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) (TA972)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 January 2026Published: 22 May 2024
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal) (TA1111)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 November 2025
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) (TA1105)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2025
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal) (TA1104)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2025
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal) (TA1100)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 October 2025
Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over (TA1085)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 30 July 2025Published: 30 July 2025
Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 June 2025
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 March 2025
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (TA1033)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 February 2025
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (TA1034)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 January 2025
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over (TA1031)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 January 2025
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (TA982)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 June 2024
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 May 2024
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 May 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 January 2024
Risdiplam for treating spinal muscular atrophy (TA755)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 15 December 2023Published: 16 December 2021
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2023
Somatrogon for treating growth disturbance in children and young people aged 3 years and over (TA863)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2023
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 July 2022
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 December 2021
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 October 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA714)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 July 2021
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) (TA701)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 May 2021
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cochlear implants for children and adults with severe to profound deafness (TA566)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 March 2019
Dinutuximab beta for treating neuroblastoma (TA538)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2018
Immunosuppressive therapy for kidney transplant in children and young people (TA482)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 July 2017
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2013
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2011
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 January 2011
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 May 2010